Cholangiocarcinoma is a malignant tumor of the digestive tract, and patients with advanced stage are prone to obstructive jaundice, so special attention should be paid to dietary modification during medication.
Patients with cholangiocarcinoma are prone to obstructive jaundice, which is manifested as yellow staining of the skin, sclera, and mucous membranes.
Patients with advanced cholangiocarcinoma may present with cholestasis and need to be alert to the risk of bacterial infection. The appearance of these symptoms should be closely monitored during medication.
Patients with advanced cholangiocarcinoma need regular reexaminations during the treatment period to confirm the changes in the disease.
It is recommended to recheck the liver ultrasound, liver CT, or magnetic resonance examination every half a month or so, so as to detect the changes in the condition in time and give corresponding treatment.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: